<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1537">
  <stage>Registered</stage>
  <submitdate>10/08/2006</submitdate>
  <approvaldate>4/09/2006</approvaldate>
  <actrnumber>ACTRN12606000386538</actrnumber>
  <trial_identification>
    <studytitle>A Pilot Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Out-Patient Based Vinorelbine, Gemcitabine and Pegfilgrastim (VGF)/Pegfilgrastim, Gemcitabine, Ifosfamide and Vinorelbine (F-GIV) Salvage Therapies in the treatment of Relapsed/Refractory CD20+ Lymphomas.</studytitle>
    <scientifictitle>A Pilot Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Out-Patient Based Vinorelbine, Gemcitabine and Pegfilgrastim or Pegfilgrastim, Gemcitabine, Ifosfamide and Vinorelbine Salvage Therapies in the Treatment of Relapsed/Refractory CD20+ Non-Hodgkin Lymphomas to Improve the Outcome of Quality of Life and to Minimise Inpatient Stay.</scientifictitle>
    <utrn />
    <trialacronym>Rituximab in Combination with Out-Patient Therapy for CD20+ Lymphoma</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00280878</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed and refractory CD20+ lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an open label, Phase II, pilot study of 12 patients using a risk-adjusted outpatient-based approach to non- Hodgkin Lymphoma salvage therapy with R-VGF (Rituximab 375mg/m2 IV, Vinorelbine 25mg/m2 IV, Gemcitabine 1000mg/m2 IV and Pegfilgrastim 6mg subcutaneous) and R-F-GIV (Rituximab 375mg/m2 IV, Gemcitabine 1000mg/m2 IV, Ifosfamide 3g/m2 IV, Vinorelbine 25mg/m2 IV and Pegfilgrastim 6mg subcutaneous. Patients will be stratified at the time of accrual to 1 of 3 groups: Good risk (Group 1), poor risk (Group 2) or post-transplant (Group 3). Patients in Groups 1 and 3 will commence treatment with R-VGF. Patients in Group 2 will commence treatment with R-F-GIV. Patients failing to show an adequate response following 2 cycles of therapy and who do not have progressive disease will escalate to a more intensive regimen for 2 further cycles of therapy (R-VGF to R-F-GIV, R-F-GIV to IVAC). IVAC comprises Etoposide 60mg/m2 IV and Ifosfamide 1.5g/m2 IV given on Day 1 to 5, Cytarabine 2g/m2 IV given on Day 1 and 2 and Pegfilgrastim 6mg subcutaneous given on Day 6 of each 21 Day cycle. The pegylated form of Filgrastim, Pegfilgrastim, will be used once per cycle instead of daily Filgrastim. Patients will receive treatment on Day 1 and 8 of every 3 week cycle.</interventions>
    <comparator>not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with Rituximab (R-VGF/R-F-GIV). 
A 20% rate of Grade 4 non-haematological toxicity would be considered excessive. Treatment with protocol therapy will be terminated if 4 out of the first 10 patients treated experience at least 1 Grade 4 non-haematological toxicity. All patients who receive any study medication will be included in the toxicity analysis.</outcome>
      <timepoint>Patients will be assessed after each cycle of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine point estimates of the response rates achieved with R-VGF or R-F-GIV in previously treated patients with relapsed/refractory CD20+ B-cell NHL.</outcome>
      <timepoint> An intention to treat analysis of response will be conducted including all patients receiving any protocol medication. Response assessment will be performed post 2 cycles of treatment and again after the completion of 4 cycles of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Relapsed or primary refractory CD20+ NHL, ECOG 0  2, Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Intention to proceed with any form of transplant therapy following fewer than 2 cycles of protocol salvage therapy, Bilirubin &gt; 50Âµmol/litre unless secondary to lymphoma, Creatinine &gt; 2 x upper limit of normal unless secondary to lymphoma, Absolute neutrophil count &lt;0.5 x 109/litre and / or platelets &lt; 50 x 109/litre unless secondary to lymphoma, Relapse within 6 months of a prior transplant procedure (autologous or allogeneic), Known sensitivity to E coli derived preparations.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/03/2006</anticipatedstartdate>
    <actualstartdate>3/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/07/2007</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Associate Professor Andrew Spencer</primarysponsorname>
    <primarysponsoraddress>Commercial Road, Melbourne 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Alfred Hospital</fundingname>
      <fundingaddress>Commercial Road, Melbourne 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the effectiveness and safety of a new outpatient chemotherapy treatment for relapsed or treatment resistant (refractory) lymphoma.</summary>
    <trialwebsite />
    <publication>Abstract presented at HSANZ 2012
A Pilot Study of Rituximab in Combination with Outpatient Based VGF/F-GIV Salvage Therapies for Relapsed/ Refractory CD20+ Lymphomas
Sant-Rayn Pasricha1, Kathryn Reed1, Stephen Opat1,2, Sharon Avery1, Andrew Spencer1,2
1The Alfred Hospital, Melbourne, Victoria, Australia
2Monash Medical Centre, Melbourne, Victoria, Australia 
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/01/2006</ethicapprovaldate>
      <hrec>AH204/05</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Associate Professor Andrew Spencer</name>
      <address>Myeloma Research Group and Clinical Haematology
The Alfred Hospital
Ground Floor South Block
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 92763392</phone>
      <fax>+61 3 92762298</fax>
      <email>aspencer@netspace.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Kate Reed</name>
      <address>Myeloma Research Group and Clinical Haematology
The Alfred Hospital
Ground Floor South Block
Commercial Road
Melbourne VIC 3004</address>
      <phone>+61 3 92763571</phone>
      <fax>+61 3 92766531</fax>
      <email>K.Reed@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Andrew Spencer</name>
      <address>C/o Malignant Haematology and Stem Cell Transplantation Service, The Alfred Hospital</address>
      <phone>+61 3 9076 3393</phone>
      <fax />
      <email>aspencer@netspace.net.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>